

PRODUCT PORTFOLIO



WHO WE ARE?



OVER **70**
FOREIGN MARKETS
WHERE WE
ARE PRESENT



3
MANUFACTURING
PLANTS



9
REPRESENTATIVE
OFFICES



NEARLY **900**
PRODUCTS IN POLAND
AND ABROAD



19
THERAPEUTIC
AREAS



~**2700**
EMPLOYEES

WHAT WE DO?

Development of innovative generic drugs

- Unique combination drugs (FDC)
- New routes of administration
- New dosage forms
- Reduction of adverse events

HOW WE DO IT?



OVER **200**
RESEARCHERS



250
PATENTS



49
DEVELOPMENT
PROJECTS



90
TECHNICAL
SOLUTIONS



37,5 M EUR
FOR R&D PROJECTS
IN 2023



3
CO-DEVELOPMENTS

Early phase clinical trials

2022

24

2023

19

2024

16







Late phase clinical trials

6

6

7

CARDIOLOGY


ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
 APIXABAN	2,5 mg 5 mg	Capsules	Available	Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
CANDESARTAN + AMLODIPINE	8 mg/5 mg 8 mg/10 mg 16 mg/5 mg 16 mg/10 mg	capsules	Available	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
 CANDESARTAN + AMLODIPINE + HCTZ	16 mg/5 mg/12,5 mg 16 mg/10 mg/12,5 mg	capsules	Available	Treatment of hypertension, particularly in patients requiring multiple drugs to achieve blood pressure control.
CILOSTAZOL	50 mg 100 mg	tablets	Available	Treatment of intermittent claudication to improve walking distance in patients without pain.
 DABIGATRAN	75 mg 110 mg 150 mg	capsules	Available	Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of DVT and PE.
EPLERENONE	25 mg 50 mg	coated tablets	Available	Treatment of heart failure post-myocardial infarction, and hypertension.
 EZETIMIBE + ROSUVASTATIN	10 mg/5 mg 10 mg/10 mg 10 mg/15 mg 10 mg/20 mg 10 mg/30 mg 10 mg/40 mg	tablets	Available	Treatment of hypercholesterolemia to lower total cholesterol and LDL cholesterol levels
PERINDOPRIL TERT-BUTYLAMINE + AMLODIPINE	4 mg/5 mg 4 mg/10 mg 8 mg/5 mg 8 mg/10 mg	tablets	Available	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
RAMIPRIL + AMLODIPINE	2,5 mg/5 mg 5 mg/5 mg 5 mg/10 mg 10 mg/5 mg 10 mg/10 mg	capsules	Available	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
RAMIPRIL + AMLODIPINE + HCTZ	5 mg/5 mg/25 mg 10 mg/5 mg/25 mg 5 mg/5 mg/12,5 mg 10 mg/10 mg/25 mg	capsules	Available	Treatment of hypertension in patients who require a combination of an ACE inhibitor, calcium channel blocker, and diuretic.
RAMIPRIL + AMLODIPINE + ROSUVASTATIN	5 mg/5 mg/10 mg 10 mg/5 mg/10 mg 10 mg/10 mg/10 mg 5 mg/5 mg/20 mg 10 mg/5 mg/20 mg 10 mg/10 mg/20 mg	capsules	Q1 2025	Management of hypertension and hypercholesterolemia.
RAMIPRIL + BISOPROLOL	2,5 mg/1,25 mg 2,5 mg/2,5 mg 5 mg/2,5 mg 5 mg/5 mg 10 mg/5 mg 10 mg/10 mg	capsules	Available	Treatment of hypertension, especially in patients where monotherapy is not sufficient.
 RAMIPRIL + INDAPAMIDE SR	5 mg/1,5 mg 10 mg/1,5 mg	modified release tablets	Available	Treatment of hypertension in patients who require a combination of an ACE inhibitor and a long-acting diuretic.
 RANOLAZINE	375 mg 500 mg 750 mg	extended release tablets	Available	Treatment of chronic angina.

RIVAROXABAN	2,5 mg 10 mg 15 mg 20 mg	coated tablets	Available	Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment and prevention of DVT and PE, and prevention of cardiovascular events in patients with coronary artery disease or peripheral artery disease.
RIVAROXABAN + ACETYLSALICYLIC ACID	2,5 mg/50 mg	tablets	Q1 2025	Reduction of the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.
ROSUVASTATIN	5 mg 10 mg 15 mg 20 mg 30 mg 40 mg	coated tablets	Available	Treatment of hypercholesterolemia and prevention of cardiovascular disease
ROSUVASTATIN + ACETYLSALICYLIC ACID	5 mg/100 mg 10 mg/100 mg 20 mg/100 mg	capsules	Available	Prevention of cardiovascular events in patients with high cholesterol and a history of heart disease.
ROSUVASTATIN + AMLODIPINE	10 mg/5 mg 10 mg/10 mg 20 mg/5 mg 20 mg/10 mg	capsules	Available	Management of hypertension and hypercholesterolemia.
TELMISARTAN + ROSUVASTATIN	40 mg/10 mg 40 mg/20 mg 80 mg/10 mg 80 mg/20 mg	coated tablets	Available	Management of hypertension and hypercholesterolemia.


CENTRAL NERVOUS SYSTEM

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
B1 + B6 + B12 VITAMIN COMPLEX	150 mg/50 mg/0,2 mg	coated tablet	Available	Treatment and prevention of vitamin B1, B6, and B12 deficiencies; supportive therapy for neuralgia and neuritis; and enhancement of nerve function and regeneration
DULOXETINE	30 mg 60 mg	enteric-coated tablets	Available	Treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain
OLANZAPINE	5 mg 10 mg	tablets	Available	Treatment of schizophrenia and bipolar disorder; also used for the management of agitation associated with schizophrenia and bipolar I mania.
OLANZAPINE ODT	5 mg 10 mg 15 mg 20 mg	orodispersible tablets	Available	Treatment of schizophrenia and bipolar disorder; designed for patients who have difficulty swallowing tablets.
PREGABALIN	25 mg 50 mg 75 mg 100 mg 150 mg 200 mg 225 mg 300 mg	capsules	Available	Treatment of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury; management of fibromyalgia; adjunctive therapy for partial-onset seizures.
VORTIOXETINE HYDROBROMIDE	5 mg 10 mg 15 mg 20 mg	coated tablets	Q2 2025	Treatment of major depressive disorder in adults.

DIABETOLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
DAPAGLIFLOZIN	5 mg 10 mg	tablets	Q2 2026	Treatment of type 2 diabetes mellitus to improve glycemic control, treatment of heart failure and chronic kidney disease.
DAPAGLIFLOZIN + SITAGLIPTIN	10 mg/100 mg	coated tablets	Q4 2026	Treatment of type 2 diabetes mellitus to improve glycemic control in adults when treatment with both dapagliflozin and sitagliptin is appropriate.
EMPAGLIFLOZIN	10 mg 25 mg	coated tablets	Q2 2025	Treatment of type 2 diabetes mellitus to improve glycemic control, reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
EMPAGLIFLOZIN + LINAGLIPTIN	10 mg/5 mg 25 mg/5 mg	coated tablets	Q4 2026	Treatment of type 2 diabetes mellitus to improve glycemic control in adults when treatment with both empagliflozin and linagliptin is appropriate.
EMPAGLIFLOZIN + LINAGLIPTIN + METFORMIN IR	5 mg/2,5 mg/850 mg 5 mg/2,5 mg/1000 mg 2,5 mg/2,5 mg/850 mg 12,5 mg/2,5 mg/1000 mg	coated tablets	Q1 2028	Treatment of type 2 diabetes mellitus to improve glycemic control in adults when treatment with empagliflozin, linagliptin, and metformin is appropriate.
 LINAGLIPTIN	5 mg	coated tablets	Available	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, used as monotherapy or in combination with other antidiabetic agents.
SITAGLIPTIN	25 mg 50 mg 100 mg	coated tablets	Available	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, used as monotherapy or in combination with other antidiabetic agents.
SITAGLIPTIN + METFORMIN XR	50 mg/500 mg 50 mg/1000 mg 100 mg/1000 mg	extended release tablets	Available	Treatment of type 2 diabetes mellitus to improve glycemic control in adults, when treatment with both sitagliptin and metformin is appropriate.

GYNAECOLOGY AND UROLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
SILDENAFIL	25 mg 50 mg 100 mg	coated tablets	Available	Treatment of erectile dysfunction.
SOLIFENACIN + TAMSULOSIN OCAS®	6 mg/0,4 mg	extended release tablets	Available	Treatment of moderate to severe storage symptoms (e.g., urgency, frequency, and incontinence) and voiding symptoms (e.g., weak stream, straining, and incomplete emptying) associated with benign prostatic hyperplasia (BPH) in men.
TADALAFIL + TAMSULOSIN OCAS®	5 mg/0,4 mg	bi-layer tablet	Q4 2027	Treatment of benign prostatic hyperplasia (BPH) to improve symptoms, including urinary frequency, urgency, and weak stream.
 TRANEXAMIC ACID	500 mg 1000 mg	tablets	Available	Treatment and prevention of excessive bleeding, including heavy menstrual bleeding, hereditary angioedema, and bleeding associated with surgery, trauma, or dental procedures.

ONCOLOGY

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
ABIRATERONE	250 mg 500 mg	coated tablets	Available	Treatment of metastatic castration-resistant prostate cancer, in combination with prednisone or prednisolone.
BORTEZOMIB	3,5 mg	vial	Available	Treatment of multiple myeloma and mantle cell lymphoma, as monotherapy or in combination with other agents.
IMATINIB	100 mg 400 mg	capsules	Available	Treatment of various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and other malignancies with specific genetic mutations.
SUNITINIB	12,5 mg 25 mg 37,5 mg 50 mg	capsules	Available	Treatment of various types of cancer, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib, and pancreatic neuroendocrine tumors (pNET).

OTHER THERAPY GROUPS

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
AZITHROMYCIN	250 mg 500 mg	coated tablets	Available	Treatment of various bacterial infections, including respiratory infections, skin infections, ear infections, and sexually transmitted diseases;
DEXAMETHASONE	4 mg 8 mg 20 mg	tablets	Available	Treatment of inflammation, allergic reactions, autoimmune conditions, and certain types of cancer; also used to manage cerebral edema, adrenal insufficiency, and as an antiemetic in chemotherapy.
FLUDROCORTISONE	0,1 mg	tablets	Available	Treatment of adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
RISEDRONATE SODIUM	35 mg 75 mg	coated tablets	Available	Treatment and prevention of osteoporosis in postmenopausal women and men; treatment of Paget's disease of bone.
OSELTAMIVIR	75 mg	powder for oral solution	Q1 2025	Treatment and prevention of influenza A and B in adults and children; should be administered within 48 hours of symptom onset for maximum effectiveness.

OVER THE COUNTER

ACTIVE SUBSTANCE	DOSE	PHARMACEUTICAL FORM	DOSSIER AVAILABILITY DATE	MOLECULE(S) INDICATION
CYTISINE	1,5 mg	coated tablets	Available	Smoking cessation aid to reduce nicotine withdrawal symptoms and cravings associated with quitting smoking.
 CYTISINE	1,5 mg	oral solution (spray)	Available	Smoking cessation aid to reduce nicotine withdrawal symptoms and cravings associated with quitting smoking.
FURAZIDIN ALSO AVAILABLE AS RX	50 mg 100 mg	tablets	Available	Treatment of urinary tract infections (UTIs) caused by susceptible bacteria.
LEVODROPROPIZINE	60 mg/ml	oral drops, solution	Q1 2026	Symptomatic treatment of cough in various respiratory conditions.
LEVODROPROPIZINE	60 mg	orodispersible tablets	Q1 2026	Symptomatic treatment of cough in various respiratory conditions.
 MINOXIDIL	5%	foam	Available	Treatment of androgenetic alopecia (pattern hair loss) in men and women.
 SILDENAFIL	25 mg 50 mg*	coated tablets	Available	Treatment of erectile dysfunction.

*Available in Rx status



Pienkow, M. Adamkiewicza 6A Str, 05-152 Czosnow, Poland
tel.: +48 22 732 77 00, fax: +48 22 732 78 00
e-mail: LicenseOut@adamed.com
www.adamed.com